The laboratory diagnosis of testosterone deficiency
- PMID: 24548716
- DOI: 10.1016/j.urology.2013.12.024
The laboratory diagnosis of testosterone deficiency
Abstract
The evaluation and treatment of hypogonadal men has become an important part of urologic practice. Fatigue, loss of libido, and erectile dysfunction are commonly reported, but nonspecific symptoms and laboratory verification of low testosterone (T) are an important part of evaluation in addition to a detailed history and physical examination. Significant intraindividual fluctuations in serum T levels, biologic variation of T action on end organs, the wide range of T levels in human serum samples, and technical limitations of currently available assays have led to poor reliability of T measurements in the clinical laboratory setting. There is no universally accepted threshold of T concentration that distinguishes eugonadal from hypogonadal men; thus, laboratory results have to be interpreted in the appropriate clinical setting. This review focuses on clinical, biological, and technological challenges that affect serum T measurements to educate clinicians regarding technological advances and limitations of the currently available laboratory methods to diagnose hypogonadism. A collaborative effort led by the American Urological Association between practicing clinicians, patient advocacy groups, government regulatory agencies, industry, and professional societies is underway to provide optimized assay platforms and evidence-based normal assay ranges to guide clinical decision making. Until such standardization is commonplace in clinical laboratories, the decision to treat should be based on the presence of signs and symptoms in addition to serum T measurements. Rigid interpretation of T ranges should not dictate clinical decision making or define coverage of treatment by third party payers.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.Postgrad Med. 2013 Mar;125(2):30-9. doi: 10.3810/pgm.2013.03.2639. Postgrad Med. 2013. PMID: 23816769
-
The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders.Steroids. 2008 Dec 12;73(13):1311-7. doi: 10.1016/j.steroids.2008.07.003. Epub 2008 Jul 17. Steroids. 2008. PMID: 18687348
-
Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.J Endocrinol Invest. 2005;28(3 Suppl):23-7. J Endocrinol Invest. 2005. PMID: 16042356
-
The laboratory assessment of partial androgen deficiency of the aging male.J Endocrinol Invest. 2005;28(11 Suppl Proceedings):39-42. J Endocrinol Invest. 2005. PMID: 16760623 Review.
-
A critical appraisal of accuracy and cost of laboratory methodologies for the diagnosis of hypogonadism: the role of free testosterone assays.Can J Urol. 2012 Jun;19(3):6314-8. Can J Urol. 2012. PMID: 22704323 Review.
Cited by
-
Association of serum testosterone with chronic obstructive pulmonary disease (COPD) in a nationally representative sample of White, Black, and Hispanic men.Hormones (Athens). 2024 Mar;23(1):153-162. doi: 10.1007/s42000-023-00506-x. Epub 2023 Dec 8. Hormones (Athens). 2024. PMID: 38064143 Free PMC article.
-
Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQCML/SEEN/SEEP.Adv Lab Med. 2023 Mar 9;4(1):52-69. doi: 10.1515/almed-2023-0020. eCollection 2023 Apr. Adv Lab Med. 2023. PMID: 37359897 Free PMC article.
-
Putative adverse outcome pathways for silver nanoparticle toxicity on mammalian male reproductive system: a literature review.Part Fibre Toxicol. 2023 Jan 5;20(1):1. doi: 10.1186/s12989-022-00511-9. Part Fibre Toxicol. 2023. PMID: 36604752 Free PMC article.
-
Association of total and free testosterone with cardiovascular disease in a nationally representative sample of white, black, and Mexican American men.Int J Impot Res. 2024 Jun;36(4):385-393. doi: 10.1038/s41443-022-00660-7. Epub 2022 Dec 29. Int J Impot Res. 2024. PMID: 36581758 Free PMC article.
-
Is Oral Testosterone the New Frontier of Testosterone Replacement Therapy?Cureus. 2022 Aug 8;14(8):e27796. doi: 10.7759/cureus.27796. eCollection 2022 Aug. Cureus. 2022. PMID: 36106278 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
